Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (ISRCTN83573069) titled 'A study to look at the safety of a new medicine called AKV9, and how the body processes it, in healthy adults' on Oct. 19.
Study Type: Interventional
Study Design:
Allocation: Randomized controlled trial
Masking: Blinded (masking used)
Control: Placebo
Assignment: Parallel
Purpose: Treatment
Primary Sponsor: Akava Therapeutics Australia Pty Ltd
Condition:
AKV9 is being developed for treatment of neurodegenerative diseases
Nervous System Diseases
Intervention:
Two-part, single-centre study.
Part A (SAD): ~56 healthy adults in 7 sequential cohorts of 8, randomised [6:2] to a single oral dose of AKV9 ([dose ran...